Horizon Therapeutics (HZNP) stock price, revenue, and financials

Horizon Therapeutics market cap is $15.6 b, and annual revenue was $1.30 b in FY 2019

$15.6 B

HZNP Mkt cap, 27-Nov-2020

$636.4 M

Horizon Therapeutics Revenue Q3, 2020
Horizon Therapeutics Gross profit (Q3, 2020)485 M
Horizon Therapeutics Gross profit margin (Q3, 2020), %76.2%
Horizon Therapeutics Net income (Q3, 2020)292.8 M
Horizon Therapeutics EBIT (Q3, 2020)228.6 M
Horizon Therapeutics Cash, 30-Sept-20201.7 B
Horizon Therapeutics EV14.8 B

Horizon Therapeutics Revenue

Horizon Therapeutics revenue was $1.30 b in FY, 2019 which is a 7.7% year over year increase from the previous period.

Embed Graph

Horizon Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

751.4m958.7m1.1b

Accounts Receivable

367.4m464.7m408.7m

Inventories

61.7m50.8m53.8m

Current Assets

1.2b1.5b1.7b

PP&E

20.4m20.1m30.2m

Goodwill

426.4m426.4m413.7m

Total Assets

4.2b4.1b4.4b

Accounts Payable

34.7m30.3m21.5m

Short-term debt

10.6m

Current Liabilities

757.1m761.9m723.2m

Long-term debt

1.6b1.6b1.4b

Non-Current Liabilities

2.4b2.3b1.5b

Total Debt

1.6b1.6b1.4b

Common Stock

16.0k17.0k19.0k

Additional Paid-in Capital

2.2b2.4b2.8b

Retained Earnings

(1.3b)(1.3b)(605.7m)

Total Equity

991.1m1.1b2.2b

Debt to Equity Ratio

1.6 x1.5 x0.6 x

Debt to Assets Ratio

0.4 x0.4 x0.3 x

Financial Leverage

4.2 x3.9 x2 x

Horizon Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(410.5m)(74.2m)573.0m

Depreciation and Amortization

283.4m275.7m237.2m

Accounts Receivable

(61.8m)(59.7m)56.2m

Inventories

108.4m10.3m(3.3m)

Accounts Payable

(16.5m)(4.6m)(8.7m)

Cash From Operating Activities

280.2m194.5m426.3m

Purchases of PP&E

(4.3m)(4.8m)(17.9m)

Cash From Investing Activities

(101.6m)27.7m(17.9m)

Long-term Borrowings

(1.6b)(845.7m)(2.2b)

Cash From Financing Activities

58.4m(16.6m)(290.4m)

Net Change in Cash

242.3m204.2m117.9m

Interest Paid

113.8m112.5m78.0m

Income Taxes Paid

2.5m53.1m9.9m

Horizon Therapeutics Ratios

USDFY, 2017

EV/EBIT

-8.2 x

EV/CFO

11.5 x

Revenue/Employee

1.0m

Debt/Equity

1.6 x

Debt/Assets

0.4 x

Financial Leverage

4.2 x

P/E Ratio

(5.8)

Horizon Therapeutics Operating Metrics

FY, 2017FY, 2018FY, 2019

Products

11 11 10

Pre-Clinical Phase Products

2 3 3

Phase I Trials Products

3 1

Phase III Trials Products

1 2 1

Phase 3b/4 Trials Products

2 3

Post-Market Phase Products

4

Horizon Therapeutics Employee Rating

3.483 votes
Culture & Values
3.5
Work/Life Balance
3.7
Senior Management
3
Salary & Benefits
4.2
Career Opportunities
3
Source